Novo Nordisk

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk sent this email to their subscribers on February 12, 2024.



 

 

Bagsværd, Denmark, 12 February 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons.

Please find below a statement of such trading in shares issued by Novo Nordisk.

 Details of the person discharging managerial responsibilities/person closely associated
a)Name of the Board member/Executive/Associated PersonLudovic Helfgott 
2 Reason for the notification 
a)Position/statusExecutive Vice President 
b)Initial notification/AmendmentInitial notification 
3 Details of the issuer 
a)NameNovo Nordisk A/S 
b)LEI549300DAQ1CVT6CXN342 
4 Details of the transaction(s) 
a)Description of the financial instrument,
type of instrument,
Shares

 
 Identification codeNovo Nordisk B DK0062498333 
b)Nature of the transactionSale of shares 
c)







Price(s) and volume(s)







     
 Price(s)Volume(s)  
 DKK 824.0020,000 shares  
     
     
d)Aggregated information
  • Aggregated volume
  • Price


20,000 shares
DKK 824.00
 
e)Date of the transaction2024-02-09 
f)Place of the transactionNasdaq Copenhagen 


 Details of the person discharging managerial responsibilities/person closely associated
a)Name of the Board member/Executive/Associated PersonDoug Langa 
2 Reason for the notification 
a)Position/statusExecutive Vice President 
b)Initial notification/AmendmentInitial notification 
3 Details of the issuer 
a)NameNovo Nordisk A/S 
b)LEI549300DAQ1CVT6CXN342 
4 Details of the transaction(s) 
a)Description of the financial instrument,
type of instrument,
Shares

 
 Identification codeNovo Nordisk B DK0062498333 
b)Nature of the transactionSale of shares 
c)







Price(s) and volume(s)







     
 Price(s)Volume(s)  
 DKK 823.8319,461 shares  
     
     
d)Aggregated information
  • Aggregated volume
  • Price


19,461 shares
DKK 823.83
 
e)Date of the transaction2024-02-08 
f)Place of the transactionNasdaq Copenhagen 

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 63,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

Contacts for further information

Media: 
Ambre James-Brown
+45 3079 9289
[email protected]

Elizabeth DeLuca (US)
+1 609 580 9868
[email protected]

Investors: 
Daniel Muusmann Bohsen
+45 3075 2175
[email protected]

Frederik Taylor Pitter
+45 3075 8259 [email protected]
David Heiberg Landsted
+45 3077 6915
[email protected]

Mark Joseph Root (US)
+1 848 213 3219
[email protected]

Sina Meyer
+45 3079 6656 [email protected]

 

Company Announcement No 13 / 2024

Attachment

For more details about Novo Nordisk, please visit www.novonordisk.com;

Dear subscriber to Novo Nordisk press releases/company announcements
We use your email address to send you news from Novo Nordisk. If you want to know how we comply with data privacy protection, you can read more here:
. If you don’t want to subscribe anymore, 

 

 

Text-only version of this email

Bagsværd, Denmark, 12 February 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons. Please find below a statement of such trading in shares issued by Novo Nordisk.  Details of the person discharging managerial responsibilities/person closely associated a)Name of the Board member/Executive/Associated PersonLudovic Helfgott 2 Reason for the notification a)Position/statusExecutive Vice President b)Initial notification/AmendmentInitial notification 3 Details of the issuer a)NameNovo Nordisk A/S b)LEI549300DAQ1CVT6CXN342 4 Details of the transaction(s) a)Description of the financial instrument, type of instrument,Shares   Identification codeNovo Nordisk B DK0062498333 b)Nature of the transactionSale of shares c) Price(s) and volume(s)       Price(s)Volume(s)   DKK 824.0020,000 shares            d)Aggregated information * Aggregated volume * Price 20,000 shares DKK 824.00 e)Date of the transaction2024-02-09 f)Place of the transactionNasdaq Copenhagen   Details of the person discharging managerial responsibilities/person closely associated a)Name of the Board member/Executive/Associated PersonDoug Langa 2 Reason for the notification a)Position/statusExecutive Vice President b)Initial notification/AmendmentInitial notification 3 Details of the issuer a)NameNovo Nordisk A/S b)LEI549300DAQ1CVT6CXN342 4 Details of the transaction(s) a)Description of the financial instrument, type of instrument,Shares   Identification codeNovo Nordisk B DK0062498333 b)Nature of the transactionSale of shares c) Price(s) and volume(s)       Price(s)Volume(s)   DKK 823.8319,461 shares            d)Aggregated information * Aggregated volume * Price 19,461 shares DKK 823.83 e)Date of the transaction2024-02-08 f)Place of the transactionNasdaq Copenhagen  Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 63,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube. Contacts for further information Media: Ambre James-Brown +45 3079 9289 [email protected] Elizabeth DeLuca (US) +1 609 580 9868 [email protected] Investors: Daniel Muusmann Bohsen +45 3075 2175 [email protected] Frederik Taylor Pitter +45 3075 8259 [email protected] Heiberg Landsted +45 3077 6915 [email protected] Mark Joseph Root (US) +1 848 213 3219 [email protected] Sina Meyer +45 3079 6656 [email protected] Company Announcement No 13 / 2024 Attachment * CA240112-Insider-trading For more details about Novo Nordisk, please visit www.novonordisk.com; Dear subscriber to Novo Nordisk press releases/company announcements We use your email address to send you news from Novo Nordisk. If you want to know how we comply with data privacy protection, you can read more here: . If you don’t want to subscribe anymore,   
Show all

The Latest Emails Sent By Novo Nordisk

More Emails, Deals & Coupons From Novo Nordisk

Email Offers, Discounts & Promos From Our Top Stores